Table 7.
Pregnancy outcomes by case severity
| Outcome | Pregnant severe cases (n=29), n/N (%) | Pregnant critical cases (n=9), n/N (%) |
|---|---|---|
| Mode of deliverya | ||
| Cesarean delivery | 10/15 (66.7) | 6/7 (85.7) |
| Vaginal delivery | 5/15 (33.3) | 1/7 (14.3) |
| Indication for deliverya | ||
| Maternal status | 9/15 (60.0) | 6/7 (85.7) |
| Fetal status | 1/15 (6.7) | 0/7 (0.0) |
| Obstetrical indications | 5/15 (33.3) | 1/7 (14.3) |
| Prenatal complications | ||
| Pregnancy-related hypertensive disorders | 0/29 (0.0) | 1/9 (11.1) |
| Gestational diabetes | 1/29 (3.4) | 0/9 (0.0) |
| Other prenatal complications | 4/29 (13.8) | 0/9 (0.0) |
| Obstetrical complications | ||
| Hypertensive disorder of pregnancy | 2/29 (6.9) | 1/9 (11.1) |
| Presumed IAI | 1/29 (3.4) | 0/9 (0.0) |
| Preterm labor | 1/29 (3.4) | 0/9 (0.0) |
| Other obstetrical complications | 2/29 (6.9) | 0/9 (0.0) |
| Maternal Morbidity | ||
| Postpartum hemorrhage | 0/29 (0.0) | 1/9 (11.1) |
| Blood product transfusion | 0/29 (0.0) | 1/9 (11.1) |
| Other outcomes | ||
| Fetal demisea | 2/15 (13.3) | 0/7 (0.0) |
| Betamethasone for fetal lung maturity | 5/29 (17.2) | 1/9 (11.1) |
| Magnesium sulfate for fetal neuroprotection | 2/29 (6.9) | 2/9 (22.2) |
| Magnesium sulfate for PEC or HTN | 2/29 (6.9) | 0/9 (0.0) |
HTN, hypertension; IAI, intraamniotic infection; PEC, preeclampsia.
DeBolt et al. Severe and critical COVID-19 in pregnant vs nonpregnant controls. Am J Obstet Gynecol 2021.
a
At the time of data analysis, 22 (58%) pregnant patients underwent delivery (15 patients in the severe group and 7 patients in the critical group).